October 6-7, 2022

Milan, Italy - Cloisters of San Barnaba

Chairs:
Pietro Lampertico and Heiner Wedemeyer

Access to Reserved Area

In case of non-receipt of the activation email click here

Program

October 6, 2022

3.00 - 4.00 pm Registration, Poster set-up and welcome coffee
   
Opening Session
4.00 - 4.15 pm Welcome by Chairs
P. Lampertico and H. Wedemeyer
   
Session 1 - Virology and Pathogenesis
Moderators: M. Dandri and H. Wedemeyer
4.15 - 4.35 pm The HDV virus: the challenge
S. Urban
4.35 - 4.55 pm Pathogenesis of HDV: new insights
J. Lucifora
4.55 - 5.15 pm Immunology of HDV in untreated and treated patients
H. Kefalakes
5.15 - 5.30 pm Discussion
   
Session 2 - Epidemiology and Diagnosis
Moderators: F. Caruntu and R. Gish
5.30 - 5.50 pm Epidemiology of HDV: from low to high endemic countries
S. Hamid
5.50 - 6.10 pm Epidemiology of HDV in North America: a forgotten disease?
N. Reau
6.10 - 6.30 pm Diagnosis of HDV: clinical virology and new HBV biomarkers
M. Brunetto
6.30 - 6.45 pm Discussion
   
6.45 - 7.25 pm KEYNOTE LECTURE
From HDV discovery to perspectives of cure
Moderators: P. Lampertico and H. Wedemeyer
Speaker: M. Rizzetto
7.25 - 8.15 pm Apero and DZIF Poster Session
8.15 - 10.30 pm Dinner

October 7, 2022

8.00 - 8.30 am Welcome breakfast
8.30 - 8.45 am Opening remarks Day 2
P. Lampertico and H. Wedemeyer
   
Session 3 - Diagnosis and Natural History
Moderators: P. Lampertico and N. Reau
8.45 - 9.05 am Non-invasive markers of fibrosis in CHD: pros and cons
L. Castera
9.05 - 9.25 am Natural history of untreated HDV patients: always a progressive disease?
S. Aleman
9.25 - 9.45 am Endpoints of HDV therapy
M. Buti
9.45 - 10.10 am Discussion
   
10.10 - 10.40 am Coffee Break and DZIF Poster Session
   
Session 4 - Antiviral Treatment I
Moderators: M. Cornberg and D. Roulot
10.40 - 11.00 am Peginterferon therapy: effectiveness, predictors, and long-term outcomes
T. Asselah
11.00 - 11.20 am Bulevirtide with or without peginterferon alfa: clinical trials
H. Wedemeyer
11.20 - 11.50 am Bulevirtide with or without peginterferon alfa: real-world studies
P. Lampertico
11.50 - 12.15 am Discussion
   
12.15 - 1.30 pm Lunch Break and DZIF Poster Session
   
Session 5 - Antiviral Treatment II
Moderators: K. Agarwal and V. de L├ędinghen
1.30 - 1.50 pm Lonafarnib with or without peginterferon alpha/lambda
C. Yurdaydin
1.50 - 2.10 pm Anti-HBV drugs targeting HBsAg
F. Zoulim
2.10 - 2.30 pm Discussion
   
Session 6 - Round Table Discussion
Moderators: P. Lampertico and H. Wedemeyer
2.30 - 3.45 pm Hot topics in HDV management.
Academia, Pharma and Diagnostics representatives
  - For Academia: S. Aleman, V. de L├ędinghen, N. Reau, F. Zoulim
- For Pharma and Diagnostics: M. Biermer, I. Choong, G. Cloherty, J.F. Flaherty, C. Hwang, A. Reinhardt, C. Simon
3.45 - 4.00 pm Closing remarks
P. Lampertico and H. Wedemeyer
×

×

Forgot password

Password forgot

Please enter your email address. You will receive a message with the link to reset your password.

×

Change password

Change password